Mammalian target of rapamycin as a target in hematological malignancies
作者： Kevin R. Kelly , Julie H. Rowe , Swaminathan Padmanabhan , Steffan T. Nawrocki , Jennifer S. Carew
DOI: 10.1007/S11523-011-0175-8
关键词:
摘要: The mammalian target of rapamycin (mTOR) regulates protein synthesis in addition to cell growth and proliferation. Elucidation the roles phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR pathway regulation pathogenesis hematological neoplasms has led development clinical evaluation agents targeting this for treatment leukemia lymphomas. Clinical trials conducted date have shown modest responses mTOR inhibition patients with various malignancies. Novel that simultaneously complex 2 (mTORC2) or AKT 1 (mTORC1) may offer an opportunity improve therapeutic efficacy.
springer.com
sci-hub.se 参考文章(85)
Andrzej S. Tarnawski, Eric C. Chu, PTEN regulatory functions in tumor suppression and cell biology. Medical Science Monitor. ,vol. 10, ,(2004)
Teresa Hyun, Alan Yam, Salvatore Pece, Xiaozhen Xie, Jie Zhang, Toru Miki, J. Silvio Gutkind, Weiqun Li, Loss of PTEN expression leading to high Akt activation in human multiple myelomas. Blood. ,vol. 96, pp. 3560- 3568 ,(2000) , 10.1182/BLOOD.V96.10.3560
Laleh Shayesteh, Yiling Lu, Wen-Lin Kuo, Russell Baldocchi, Tony Godfrey, Colin Collins, Daniel Pinkel, Bethan Powell, Gordon B. Mills, Joe W. Gray, PIK3CA is implicated as an oncogene in ovarian cancer Nature Genetics. ,vol. 21, pp. 99- 102 ,(1999) , 10.1038/5042
Amer M. Mirza, Martin McMahon, Richard A. Roth, Aimee D. Kohn, Oncogenic Transformation of Cells by a Conditionally Active Form of the Protein Kinase Akt/PKB Cell Growth & Differentiation. ,vol. 11, pp. 279- 292 ,(2000)
Estela Jacinto, Michael N. Hall, Tor signalling in bugs, brain and brawn. Nature Reviews Molecular Cell Biology. ,vol. 4, pp. 117- 126 ,(2003) , 10.1038/NRM1018
Devalingam Mahalingam, Kamalesh Sankhala, Alain Mita, Francis J Giles, Monica M Mita, None, Targeting the mTOR pathway using deforolimus in cancer therapy. Future Oncology. ,vol. 5, pp. 291- 303 ,(2009) , 10.2217/FON.09.9
Thomas Decker, Susanne Hipp, Ingo Ringshausen, Christian Bogner, Madlene Oelsner, Folker Schneller, Christian Peschel, Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood. ,vol. 101, pp. 278- 285 ,(2003) , 10.1182/BLOOD-2002-01-0189
Zhihong Zeng, Dos D. Sarbassov, Ismael J. Samudio, Karen W. L. Yee, Mark F. Munsell, C. Ellen Jackson, Francis J. Giles, David M. Sabatini, Michael Andreeff, Marina Konopleva, Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML Blood. ,vol. 109, pp. 3509- 3512 ,(2007) , 10.1182/BLOOD-2006-06-030833
Récher Christian, Dos Santos Cédric, Demur Cécile, Payrastre Bernard, mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle. ,vol. 4, pp. 1540- 1549 ,(2005) , 10.4161/CC.4.11.2159
Eduardo Vilar, Jose Perez-Garcia, Josep Tabernero, None, Pushing the Envelope in the mTOR Pathway: The Second Generation of Inhibitors Molecular Cancer Therapeutics. ,vol. 10, pp. 395- 403 ,(2011) , 10.1158/1535-7163.MCT-10-0905